Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of DZD9008 in Advanced NSCLC with EGFR or HER2 Mutation
jRCT2061210046Phase 2Active, not recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of sunvozertinib in EGFR-mutated non-small cell lung cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of DZD9008. Started Jan 2022; status: active, not recruiting.
02
Drugs
sunvozertinib
03
Conditions
EGFR-mutated non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061210046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210046.